342 related articles for article (PubMed ID: 26134383)
21. 4D- quantitative structure-activity relationship modeling: making a comeback.
Fourches D; Ash J
Expert Opin Drug Discov; 2019 Dec; 14(12):1227-1235. PubMed ID: 31513441
[No Abstract] [Full Text] [Related]
22. Have artificial neural networks met expectations in drug discovery as implemented in QSAR framework?
Dobchev D; Karelson M
Expert Opin Drug Discov; 2016 Jul; 11(7):627-39. PubMed ID: 27149299
[TBL] [Abstract][Full Text] [Related]
23. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Prado-Prado FJ; Martinez de la Vega O; Uriarte E; Ubeira FM; Chou KC; González-Díaz H
Bioorg Med Chem; 2009 Jan; 17(2):569-75. PubMed ID: 19112024
[TBL] [Abstract][Full Text] [Related]
24. Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents.
Ambure P; Roy K
Expert Opin Drug Discov; 2014 Jun; 9(6):697-723. PubMed ID: 24754675
[TBL] [Abstract][Full Text] [Related]
25. Development of quantitative structure-activity relationships and its application in rational drug design.
Yang GF; Huang X
Curr Pharm Des; 2006; 12(35):4601-11. PubMed ID: 17168765
[TBL] [Abstract][Full Text] [Related]
26. 3D-QSAR and molecular docking for the discovery of ketolide derivatives.
Ruan ZX; Huangfu DS; Xu XJ; Sun PH; Chen WM
Expert Opin Drug Discov; 2013 Apr; 8(4):427-44. PubMed ID: 23441865
[TBL] [Abstract][Full Text] [Related]
27. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
Desai PV; Sawada GA; Watson IA; Raub TJ
Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
[TBL] [Abstract][Full Text] [Related]
28. New in silico and conventional in vitro approaches to advance HIV drug discovery and design.
Maga G; Veljkovic N; Crespan E; Spadari S; Prljic J; Perovic V; Glisic S; Veljkovic V
Expert Opin Drug Discov; 2013 Jan; 8(1):83-92. PubMed ID: 23167743
[TBL] [Abstract][Full Text] [Related]
29. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
30. Chemical graphs, molecular matrices and topological indices in chemoinformatics and quantitative structure-activity relationships.
Ivanciuc O
Curr Comput Aided Drug Des; 2013 Jun; 9(2):153-63. PubMed ID: 23701000
[TBL] [Abstract][Full Text] [Related]
31. Systematic generation of chemical structures for rational drug design based on QSAR models.
Funatsu K; Miyao T; Arakawa M
Curr Comput Aided Drug Des; 2011 Mar; 7(1):1-9. PubMed ID: 20550510
[TBL] [Abstract][Full Text] [Related]
32. Editorial: The Expanding Landscape of Graph Theoretic Molecular Descriptors: Development, Gradual Diversification of Descriptor Space, and Applications in QSAR/ QMSA and New Drug Discovery.
Basak SC
Curr Comput Aided Drug Des; 2017; 13(3):172-176. PubMed ID: 29517467
[No Abstract] [Full Text] [Related]
33. Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR.
Tropsha A; Isayev O; Varnek A; Schneider G; Cherkasov A
Nat Rev Drug Discov; 2024 Feb; 23(2):141-155. PubMed ID: 38066301
[TBL] [Abstract][Full Text] [Related]
34. Challenges with multi-objective QSAR in drug discovery.
Lambrinidis G; Tsantili-Kakoulidou A
Expert Opin Drug Discov; 2018 Sep; 13(9):851-859. PubMed ID: 29996683
[TBL] [Abstract][Full Text] [Related]
35. From Classification to Regression Multitasking QSAR Modeling Using a Novel Modular Neural Network: Simultaneous Prediction of Anticonvulsant Activity and Neurotoxicity of Succinimides.
Antanasijević D; Antanasijević J; Trišović N; Ušćumlić G; Pocajt V
Mol Pharm; 2017 Dec; 14(12):4476-4484. PubMed ID: 29130688
[TBL] [Abstract][Full Text] [Related]
36. Quantitative structure-activity relationship models for compounds with anticonvulsant activity.
Bellera CL; Talevi A
Expert Opin Drug Discov; 2019 Jul; 14(7):653-665. PubMed ID: 31072145
[No Abstract] [Full Text] [Related]
37. Monoamino oxidase a: an interesting pharmacological target for the development of multi-target QSAR.
Molina E; Sobarzo-Sanchez E; Speck-Planche A; Matos MJ; Uriarte E; Santana L; Yanez M; Orallo F
Mini Rev Med Chem; 2012 Sep; 12(10):947-58. PubMed ID: 22420572
[TBL] [Abstract][Full Text] [Related]
38. Physicochemical Significance of Topological Indices: Importance in Drug Discovery Research.
Bhatia KS; Gupta AK; Saxena AK
Curr Top Med Chem; 2023; 23(29):2735-2742. PubMed ID: 37519204
[TBL] [Abstract][Full Text] [Related]
39. Application of SMILES Notation Based Optimal Descriptors in Drug Discovery and Design.
Veselinović AM; Veselinović JB; Živković JV; Nikolić GM
Curr Top Med Chem; 2015; 15(18):1768-79. PubMed ID: 25961525
[TBL] [Abstract][Full Text] [Related]
40. New insights toward the discovery of antibacterial agents: multi-tasking QSBER model for the simultaneous prediction of anti-tuberculosis activity and toxicological profiles of drugs.
Speck-Planche A; Kleandrova VV; Cordeiro MN
Eur J Pharm Sci; 2013 Mar; 48(4-5):812-8. PubMed ID: 23376211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
